Table 1 Patient characteristics
Parameter | Value |
|---|---|
Total number of patients | 52 |
Age, years (mean ± SD) | 71.5 ± 9 |
PSA at first PET/CT (ng/ml), median (IQR) | 6.6 (1.3–28.3) |
PSA at second PET/CT (ng/ml), median (IQR) | 1.6 (0.3–12.1) |
Gleason score (n) | |
6 | 6 (11.5%) |
7 | 2 (3.8%) |
7 (3 + 4) | 8 (15.4%) |
7 (4 + 3) | 6 (11.5%) |
8 | 9 (17.3%) |
9 | 12 (23.1%) |
10 | 2 (3.8%) |
n/a | 7 (13.5%) |
Disease extent demonstrated on first PET/CT (n) | |
Prostatic disease | 29 (55.8%) |
Bone metastases | 32 (61.5%) |
Lymph nodes | 42 (80.8%) |
Liver metastases | 2 (3.8%) |
Peritoneal implants | 2 (3.8%) |
Lung metastases | 1 (1.9%) |
Treatment received between the two PET/CT scans (n) | |
Hormonal therapy | 42 (80.8%) |
Salvage radiotherapy | 17 (32.7%) |
Chemotherapy | 12 (23.1%) |
Radium-223 | 2 (3.8%) |